Efficacy and safety of transcutaneous electrical acupoint stimulation for the management of primary dysmenorrhoea: protocol for a randomised controlled trial in China.

INTRODUCTION: Primary dysmenorrhoea (PD) is a common menstrual concern with significant physical and psychosocial impacts. The effectiveness and safety of transcutaneous electrical acupoint stimulation (TEAS) in alleviating PD symptoms remain uncertain due to insufficient evidence. This single-centre, parallel, randomised controlled study intends to evaluate the efficacy and safety of TEAS for PD management. METHODS AND ANALYSIS: 60 participants aged 18-40 years diagnosed with moderate to severe PD will be recruited from Tai'an Hospital of Traditional Chinese Medicine (TCM) and randomly assigned to either a TEAS group or a TEAS-sham group (1:1). The TEAS group will undergo 12 sessions of TEAS treatment over two menstrual cycles, with 30 min per session, three sessions weekly. Participants in the TEAS-sham group will receive TEAS stimulation using identical devices and protocols but without current output. The primary outcome is the Visual Analogue Scale (VAS) for pain assessment. Secondary outcomes are Short-Form McGill Pain Questionnaire, total effective rate, uterine artery haemodynamics, prostaglandin and ß-endorphin level, mental well-being and quality of life. Adverse events and their potential reasons and the use of analgesics will also be recorded. ETHICS AND DISSEMINATION: This study was approved by the Medical Ethics Committee of Tai'an Hospital of TCM. Written informed consent will be obtained from each participant. The results will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: ChiCTR2300071686.

Mixed lead source precursors for producing light absorption layers of perovskite solar cells.

Beside the conventional perovskite precursors with lead halides as lead sources, non-halide lead sources provide additional tools for tuning the properties of perovskite layers, and lead acetate is a promising candidate for non-halide lead sources. In this work, we develop the perovskite precursor with a mixed non-halide lead source by partially replacing lead acetate with lead thiocyanate. Scanning electron microscopy and X-ray diffraction measurements indicate that lead thiocyanate additive can remarkably increase the size of perovskite grains and the crystallization of perovskite layers. And the cross-sectional investigation illustrates that the penetration of perovskite materials into TiO2 porous layers also can be improved by the lead thiocyanate additive. As a consequence, the recombination process and charge extraction process of devices are improved. By optimizing the quantity of lead thiocyanate, the power conversion efficiency of devices is increased from 14.0% to 17.2%, and the stability of devices is elevated simultaneously.

Localized incorporation of cesium ions to improve formamidinium lead iodide layers in perovskite solar cells.

For the perovskite solar cells with formamidinium lead iodide (FAPbI3) as a light harvester, cesium ions (Cs+) can be used to stabilize the perovskite crystal structure of FAPbI3. However, the incorporation of Cs+ ions usually reduces the grain size and degrades the crystallization of FAPbI3 layers, and this is harmful to the photovoltaic performance of solar cells. In this work, we incorporate Cs+ ions into FAPbI3 layers using the interfacial doping method, which is different from the mixed solution doping method in previous reports. Elemental analysis indicates that Cs+ dopants cannot be detected at the outer surfaces of perovskite layers, and the majority of Cs+ dopants should be localized in the vicinity of TiO2/perovskite interfaces, which is remarkably different from the distribution of Cs+ dopants in the perovskite layers prepared using the mixed solution doping method. It is found that interfacial doping method can avoid the blue shift of the light absorption edge and can improve the crystallization of FAPbI3 layers. For the optimized conditions, Cs x FA1-x PbI3 solar cells prepared using the interfacial doping method achieve a power conversion efficiency (PCE) of 17.1%, which is better than the PCE of Cs x FA1-x PbI3 devices prepared using the mixed solution doping method.

[Allelopathy of grape root aqueous extracts].

Taking the tissue-cultured seedlings of grape cultivar Red Globe as test objects, this paper examined the effects of their root aqueous extracts on seedling's growth, with the allelochemicals identified by LC-MS. The results showed that 0.02 g x ml(-1) (air-dried root mass in aqueous extracts volume; the same below), 0.1 g x ml(-1), and 0.2 g x ml(-1) of the aqueous extracts inhibited the growth of the seedlings significantly, and the inhibition effect increased with increasing concentration of the extracts. The identified allelochemicals of the extracts included p-hydroxybenzoic acid, salicylic acid, phenylpropionic acid, and coumaric acid. Pot experiment showed that different concentration (0.1, 1, and 10 mmol x L(-1)) salicylic acid and phenylpropionic acid inhibited the seedling' s growth remarkably. With the increasing concentration of the two acids, the plant height, stem diameter, shoot- and root fresh mass, leaf net photosynthetic rate and starch content, and root activity of the seedlings decreased, while the leaf soluble sugar and MDA contents increased. No obvious change pattern was observed in leaf protein content.

Inositol angelates from the whole herb of Inula cappa.

A new inositol derivative, cis-1,2,3,5-trans-4,6-inositol-2,3,6-triangelate(1) along with the known l-inositol-1,2,3,5-tetra angelate(2), was isolated from the ethanolic extract of the whole plant Inula cappa and identified on the spectroscopic analysis.

Cytotoxic germacranolide sesquiterpene from Inula cappa.

A new germacranolide, inulacappolide (1), was isolated from the EtOH extract of the whole plant of Inula cappa along with 16 known compounds. The structure of inulacappolide was a rare 1(10)-saturated type of germacran-6,12-olide, identified as 2alpha-acetoxy-3beta-hydroxy-9beta-angeloyloxygermacra-4-en-6alpha,12-olide by spectral analysis (IR, HR-ESI/MS, (1)H-NMR, (13)C-NMR, HMQC, HMBC, NOESY). In vitro, it showed antiproliferative effects against human cervical cancer HeLa, human leukemia K562 and human nasopharyngeal carcinoma KB cell lines with IC(50) values of 1.2 microM, 3.8 microM and 5.3 microM, respectively.